Find information on thousands of medical conditions and prescription drugs.

Alteplase

Tissue plasminogen activator (PLAT) is a secreted serine protease which converts the proenzyme plasminogen to plasmin, a fibrinolytic enzyme. PLAT is synthesized as a single chain which is cleaved by plasmin to a two chain disulfide linked protein.This enzyme plays a role in cell migration and tissue remodeling. Increased enzymatic activity causes hyperfibrinolysis, which manifests as excessive bleeding; decreased activity leads to hypofibrinolysis which can result in thrombosis or embolism. more...

Home
Diseases
Medicines
A
8-Hour Bayer
Abacavir
Abamectin
Abarelix
Abciximab
Abelcet
Abilify
Abreva
Acamprosate
Acarbose
Accolate
Accoleit
Accupril
Accurbron
Accure
Accuretic
Accutane
Acebutolol
Aceclidine
Acepromazine
Acesulfame
Acetaminophen
Acetazolamide
Acetohexamide
Acetohexamide
Acetylcholine chloride
Acetylcysteine
Acetyldigitoxin
Aciclovir
Acihexal
Acilac
Aciphex
Acitretin
Actifed
Actigall
Actiq
Actisite
Actonel
Actos
Acular
Acyclovir
Adalat
Adapalene
Adderall
Adefovir
Adrafinil
Adriamycin
Adriamycin
Advicor
Advil
Aerobid
Aerolate
Afrinol
Aggrenox
Agomelatine
Agrylin
Airomir
Alanine
Alavert
Albendazole
Alcaine
Alclometasone
Aldomet
Aldosterone
Alesse
Aleve
Alfenta
Alfentanil
Alfuzosin
Alimta
Alkeran
Alkeran
Allegra
Allopurinol
Alora
Alosetron
Alpidem
Alprazolam
Altace
Alteplase
Alvircept sudotox
Amantadine
Amaryl
Ambien
Ambisome
Amfetamine
Amicar
Amifostine
Amikacin
Amiloride
Amineptine
Aminocaproic acid
Aminoglutethimide
Aminophenazone
Aminophylline
Amiodarone
Amisulpride
Amitraz
Amitriptyline
Amlodipine
Amobarbital
Amohexal
Amoxapine
Amoxicillin
Amoxil
Amphetamine
Amphotec
Amphotericin B
Ampicillin
Anafranil
Anagrelide
Anakinra
Anaprox
Anastrozole
Ancef
Android
Anexsia
Aniracetam
Antabuse
Antitussive
Antivert
Apidra
Apresoline
Aquaphyllin
Aquaphyllin
Aranesp
Aranesp
Arava
Arestin
Arestin
Argatroban
Argatroban
Argatroban
Argatroban
Arginine
Arginine
Aricept
Aricept
Arimidex
Arimidex
Aripiprazole
Aripiprazole
Arixtra
Arixtra
Artane
Artane
Artemether
Artemether
Artemisinin
Artemisinin
Artesunate
Artesunate
Arthrotec
Arthrotec
Asacol
Ascorbic acid
Asmalix
Aspartame
Aspartic acid
Aspirin
Astemizole
Atacand
Atarax
Atehexal
Atenolol
Ativan
Atorvastatin
Atosiban
Atovaquone
Atridox
Atropine
Atrovent
Augmentin
Aureomycin
Avandia
Avapro
Avinza
Avizafone
Avobenzone
Avodart
Axid
Axotal
Azacitidine
Azahexal
Azathioprine
Azelaic acid
Azimilide
Azithromycin
Azlocillin
Azmacort
Aztreonam
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Gene

Alternative splicing of the PLAT gene, PLAT, produces three transcripts.

Applications

Recombinant PLAT is used in diseases which feature blood clots, such as myocardial infarction and stroke. To be effective, PLAT must be administered within the first six or so hours of the attack. Because of this, only about 3% of patients qualify for this treatment. Since PLAT dissolves blood clots, there is risk of hemorrhage with its use.

Read more at Wikipedia.org


[List your site here Free!]


Clot-busting drugs to turn off heart attacks - alteplase and streptokinase
From FDA Consumer, 2/1/88 by Catherine Carey

Clot-Busting Drugs To Turn Off Heat Attacks

Every year, about 1.5 million Americans suffer a heart attack. Of that number, one-third die within one year, 100,000 before they can be hospitalized. Typically, a blood clot develops in one of the arteries to the heart, preventing oxygen-rich blood from that part of the heart muscle. The greater the blockage and the longer it continues, the more of the heart muscle that is lost. Substantial loss of heart muscle can lead to heart failure and death.

But over the past several years, researchers have developed drugs called thrombolytic agents that can help dissolve the clots. Blood can then again flow through the artery, preventing further damage to the heart. last fall, FDA approved alteplase (trade name Activase), one of a new class of thrombolytic agents known as tissue plasminogen activators (TPA). In addition, FDA approved the expanded use of another thrombolytic agent, streptokinase (trade names Kabikinase and Streptase). These approvals mean that heart attack victims have greater reason for hope than ever before that they will successfully recover from their attacks.

Alteplase is a genetically engineered copy of a protein produced naturally by the body. In 1979, scientists in Belgium first purified TPA and showed that it could dissolve clots in laboratory animals. But the amount produced in the body, or from most human cells in culture, is so minute that large-scale production would be impractical. So, in 1981, Genentech Inc., of South San Francisco, Calif., began using recombinant DNA technology to produce enough alteplase to be tested in heart attack victims.

Genetically engineered alteplase is made by introducing the human gene that holds the instructions for producing the protein into cells originally derived from the ovaries of Chinese hamsters. The inserted gene programs the cells to consistently produce large quantities of alteplase.

Clinical trials of alteplase began in 1984. In all, Genentech's alteplase has been tested in more than 4,000 patients. It has been shown in controlled clinical trials to dissolve clots in 71 percent of heart attack patients when injected within six hours after symptoms occur. In separate trials, the drug significantly improved heart function when given within four hours.

One of the largest studies, sponsored by the National Heart, Lung, and Blood Institute, was known as the Thrombolysis in Myocardial Infarction Trial. This study included alteplase and streptokinase. Streptokinase -- made by Behringwerke AG, a German firm represented in the United States by Hoechst-Roussel Pharmaceuticals Inc. of Somerville, N.J., and KabiVitrum AB of Stockholm, Sweden, which has offices in Alameda, Calif. -- has been licensed for use in treating heart attacks since 1982. Until last fall, however, the use of streptokinase, which is derived from Streptococci bacteria, was limited because it could be administered only by inserting a catheter directly into the coronary artery. This procedure could only be done in hospitals that have special coronary care units.

But recent data from clinical trials, including one involving more than 11,000 patients, have shown that streptokinase given intravenously -- by a needle inserted into a vein -- reduces the death rate among recipients by 20 percent to 25 percent when given within six hours after a heart attack. "The most dramatic result -- a 47 percent reduction in mortality," said FDA Commissioner Frank E. Young, M.D., Ph.D., "was observed when streptokinase was administered within one hour of the onset of symptoms." In separate studies, it was shown to improve heart function.

Alteplase and streptokinase can be used to treat the vast majority of heart attack victims, but should not be given to patients at high risk of hemorrhaging. This includes patients with internal bleeding; a recent stroke, surgery or major injury; long-standing, uncontrolled high blood pressure; or a bleeding disorder. Both drugs also should be used with caution in people over 75, in pregnant women, and where bleeding is a significant hazard.

Bleeding within the brain was one of several issues that concerned the Cardiovascular and Renal Drugs Advisory Committee -- an advisory committee made up of nongovernment experts -- on May 29, 1987. This committee advised FDA to obtain more data on safety and effectiveness before approving alteplase.

Data submitted later showed that the bleeding problem occurred more frequently at higher doses, but at the recommended dose of 100 milligrams it occurred only in 0.4 percent of patients. Bleeding occurred at about the same rate with streptokinase when given at recommended dosages.

The committee also recommended FDA find out whether a change in manufacturing procedures at Genentech made any difference in alteplase's safety and effectiveness. Data submitted by the manufacturer showed that it did not. In addition, the committee questioned whether alteplase's ability to dissolve clots actually, as theorized, limited heart damage. Subsequent data showed that it did.

Robert E. Windom, M.D., assistant secretary for health, observed that although changes in diet, anti-smoking campaigns, and other factors have helped reduce deaths from heart disease, coronary heart disease "remains America's number one killer, responsible for about 768,000 deaths each year -- or about a third of all deaths," he said. "At some point in their lives," Dr. Windom added, "one out of every four or five people will feel the pain and constriction of a heart attack -- pressure or pain in their chest or pain in their left arm." When that happens, he advised, "Don't waste time hoping against hope that the pain will go away . . . get help quickly."

COPYRIGHT 1988 U.S. Government Printing Office
COPYRIGHT 2004 Gale Group

Return to Alteplase
Home Contact Resources Exchange Links ebay